|
Synonyms: ARGX-113 | efgartigimod alfa-fcab | Vyvgart®
efgartigimod alfa is an approved drug (FDA (2021), EMA (2022))
Compound class:
Antibody
Comment: Efgartigimod alfa (ARGX-113) is a first-in-class antibody fragment designed for the treatment of patients with severe autoimmune diseases associated with high levels of pathogenic immunoglobulin G (IgG) autoantibodies [6]. It binds to the IgG receptor, major histocompatibility complex class I-like Fc receptor (FcRn, the protein product of the FCGRT gene). Efgartigimod alfa inactivates FcRn's IgG binding ability (the FcRn-IgG interaction normally protects IgG from degradation) thus facilitating accelerated catabolism of native pathogenic autoantibodies [3,5]. The mechanism of this drug action is discussed more comprehensively in Roopenian and Akilesh (2007) [4] and Vaccaro et al. (2005) [7].
|
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes (FDA (2021), EMA (2022)) |
| International Nonproprietary Names |
|
| INN number | INN |
| 10455 | efgartigimod alfa |
| Synonyms |
| ARGX-113 | efgartigimod alfa-fcab | Vyvgart® |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 731 |
| Other databases | |
| GtoPdb PubChem SID | 354702250 |
| Search PubMed clinical trials | efgartigimod alfa |
| Search PubMed titles | efgartigimod alfa |
| Search PubMed titles/abstracts | efgartigimod alfa |
